Your browser doesn't support javascript.
loading
Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips, Allison L; Reeves, David J.
Affiliation
  • Phillips AL; College of Pharmacy and Health Sciences, Butler University, Indianapolis, IN, USA.
  • Reeves DJ; College of Pharmacy and Health Sciences, Butler University, Indianapolis, IN, USA.
Ann Pharmacother ; 57(6): 738-745, 2023 06.
Article in En | MEDLINE | ID: mdl-36268952
OBJECTIVE: The aim of this article is to assess available data regarding use of nivolumab/relatlimab for adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma. DATA SOURCES: A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications. STUDY SELECTION AND DATA EXTRACTION: Relevant clinical trials written in English language were analyzed. DATA SYNTHESIS: Nivolumab/relatlimab was approved by the Food and Drug Administration following results of a phase 1/2 trial and phase 2/3 RELATIVITY-047 trial. Nivolumab/relatlimab demonstrated a median progression free survival (PFS) of 10.1 months in the first-line setting without new safety signals. The PFS benefits appear greatest in those with programmed cell death-ligand 1 (PD-L1) <1% and lymphocyte activation gene-3 (LAG-3) ≥1%. Adverse effects commonly experienced were immune related in nature and require early identification and prompt management. Grade 3 or 4 adverse effects occurred in 18.9% of patients. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: For patients 12 years of age and older with unresectable or metastatic melanoma, nivolumab/relatlimab offers a new first-line treatment option. Evaluation of PD-L1 expression along with concomitant use of medications with potential interactions should be evaluated when deciding if nivolumab/relatlimab is the most appropriate treatment option. CONCLUSIONS: Nivolumab/relatlimab adds an additional first-line treatment option demonstrating promising improved PFS for patients with unresectable or metastatic melanoma, particularly those with PD-L1 <1% and/or LAG 3 ≥1%. Additional uses of nivolumab/relatlimab may be on the horizon as further clinical trials are ongoing.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma / Antineoplastic Agents Limits: Adult / Child / Humans Language: En Journal: Ann Pharmacother Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma / Antineoplastic Agents Limits: Adult / Child / Humans Language: En Journal: Ann Pharmacother Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States